Using DNA as a drug-Bioprocessing and delivery strategies

Chemical Engineering Research and Design

Volumn 87, Issue 3, 2009, Pages 343-348

  Han, Ying ^a   Liu, Shan ^a   Ho, Jenny ^a   Danquah, Michael K ^a   Forde, Gareth M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Bioprocess engineering; DNA therapeutics; Pandemic preparedness; Plasmid DNA

Indexed keywords

AFFINITY CHROMATOGRAPHY; BIOCHEMICAL ENGINEERING; BIOMOLECULES; CHROMATOGRAPHIC ANALYSIS; DNA; ENGINEERING RESEARCH; GENES; GENETIC ENGINEERING; LIGANDS; MACHINERY; ORGANIC ACIDS; PURIFICATION; QUALITY ASSURANCE; RNA; SAFETY ENGINEERING; VACCINES;

AMBIENT TEMPERATURES; BIOPROCESS ENGINEERING; BIOPROCESSING; CELLULAR MACHINERIES; DNA THERAPEUTICS; DNA VACCINES; FORWARD LOOKING; FUTURE GENERATIONS; GENE THERAPIES; GLOBAL PRODUCTIONS; PANDEMIC PREPAREDNESS; PLASMID DNA; PRODUCTION STAGES; SCALE OF PRODUCTIONS; THERAPEUTIC USE; VIRUS-LIKE PARTICLES;

NUCLEIC ACIDS;

EID: 60249091392     PISSN: 02638762     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cherd.2008.09.010     Document Type: Review

References (49)

1. Alpar H.O., Somavarapu S., Atuah K.N., and Bramwell V. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 57 3 (2005) 411-430
2. Bouchie N. Nat Biotechnol 21 (2003) 11
3. Brower V. Naked DNA vaccines come of age. Nat Biotechnol 16 13 (1998) 1304-1305
4. Centers for Disease Control and Prevention and the World Health Organization, 'History and Epidemiology of Global Smallpox Eradication'. http://www.bt.cdc.gov/agent/smallpox/training/overview/2003, Accessed 20th December 2007.
5. Cherrington C.A., Hinton M., and Chopra I. Effect of short-chain organic acids on macromolecular synthesis in Escherichia coli. J Appl Bacteriol 68 1 (1990) 69-74
6. Colpan M., and Riesner D. High-performance liquid chromatography of high molecular weight nucleic acids on the macroporous ion exchanger nucleogen. J Chromatogr 296 (1984) 339-353
7. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 1-3 (2001) 21-42
8. Donnelly J.J., Ulmer J.B., and Liu M.A. DNA vaccines. Life Sci 60 3 (1996) 163-172
9. Durland R.H., and Eastman E.M. Manufacturing and quality control of plasmid-based gene expression systems. Adv Drug Deliv Rev 30 1-3 (1998) 33-48
10. Ferreira G.N., Cabral J.M., and Prazeres D.M. Anion exchange purification of plasmid DNA using expanded bed adsorption. Bioseparation 9 (2000) 1-6
11. Green A.P., Prior G.M., Helveston N.M., Taittinger B.E., Liu X., and Thompson J.A. Preparative purification of supercoiled plasmid DNA for therapeutic applications. BioPharm (1997) 52-61
12. Greenland J.R., and Letvin N.L. Chemical adjuvants for plasmid DNA vaccines. Vaccine 25 19 (2007) 3731-3741
13. Ho, J., Wang, Huanting, Forde, G.M., 2008. Process considerations related to the microencapsulation of plasmid DNA via ultrasonic atomization, Biotechnol Bioeng, 101: 172-181.
14. Huber C.G. Micropellicular stationary phases for high-performance liquid chromatography of double-stranded DNA. J Chromatogr A 806 1 (1998) 3-30
15. Influenza Fact sheet N°211. World Health Organisation, 2003.
16. Kaslow D.C. A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases. Transac R Soc Trop Med Hyg 98 10 (2004) 593-601
17. Kieny M.P., Costa A., Hombach J., Carrasco P., Pervikov Y., Salisbury D., Greco M., Gust I., LaForce M., Franco-Paredes C., Santos J.I., D'Hondt E., Rimmelzwaan G., Karron R., and Fukuda K. A global pandemic influenza vaccine action plan. Vaccine 24 (2006) 6367-6370
18. Kuper C.F., Koornstra P.J., Hameleers D.M.H., Biewenga J., Spit B.J., Duijvestijn A.M., Vriesman P., and Sminia T. The role of nasopharyngeal lymphoid-tissue. Immunol Today 13 6 (1992) 219-224
19. Lahijani R., Hulley G., Soriano G., and Horn NA M. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 7 16 (1996) 1971-1980
20. Lahijani R., Hulley G., Soriano G., Horn N.A., and Marquet M. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 7 16 (1996) 1971-1980
21. Ledley F.D. Pharmaceutical approach to somatic gene therapy. Pharm Res 13 11 (1996) 1595-1614
22. Lee S.Y. High cell-density culture of Escherichia coli. Trends Biotechnol 14 3 (1996) 98-105
23. Liu M.A. DNA vaccines: a review. J Int Med 253 4 (2003) 402-410
24. Luli G.W., and Strohl W.R. Comparison of growth, acetate production, and acetate inhibition of Escherichia coli strains in batch and fed-batch fermentations. Appl Environ Microbiol 56 4 (1990) 1004-1011
25. Lyddiatt A., and O'Sullivan D.A. Biochemical recovery and purification of gene therapy vectors. Curr Opin Biotechnol 9 2 (1998) 177-185
26. Manoj S., Babiuk L.A., and van Drunen Littel-van den Hurk S. Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci 41 1 (2004) 1-39
27. Marquet M., Horn N.A., Meek J.A., and Pestka S. Process development for the manufacture of plasmid DNA vectors for use in gene therapy. BioPharm 20 (1995) 26-37
28. Murphy M. Pandemic vaccine "a step away". Chem Ind December (2004) 8
29. Murphy, et al. Purification of plasmid DNA using selective precipitation by compactation agents. Nat Biotechnol 17 (1999) 822-823
30. O'Kennedy R.D., Baldwin C., and Keshavarz-Moore E. Effects of growth medium selection on plasmid DNA production and initial processing steps. J Biotechnol 76 2-3 (2000) 175-183
31. Pan J., Rhee, and Lebeault J. Physiological constraints in increasing biomass concentration of Escherichia coli B in fed-batch culture. Biotechnol Lett 9 (1987) 89-94
32. Prather K.J., Sagar S., Murphy J., and Chartrain M. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb Technol 33 7 (2003) 865-883
33. Prazeres D.M.F., and Ferreira G.N.M. Design of flowsheets for the recovery and purification of plasmids for gene therapy and DNA vaccination. Chem Eng Proc Concept Proc Des 43 5 (2004) 609-624
34. Riesenberg D. High-cell density cultivation of Escherichia coli. Curr Opin Biotechnol 2 (1991) 380-384
35. Sahaa S., Takeshitaa F., Sasakia S., Matsudaa T., Tanakaa T., Tozukaa M., Takasea K., Matsumotob T., Okudac K., Ishiid N., Yamaguchib K., Klinmane D., Xina K., and Okuda K. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 24 (2006) 6240-6249
36. Schillinga R., Heila A., Langnera K., Pohlmeyera K., Larsenb M., Baumeisterc H., Goletzb S., and Behnkea B. A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains. Vaccine 24 (2006) 4648-4650
37. Schluep T., and Cooney C.L. Purification of plasmid DNA by triplex affinity interactions. Nucleic Acids Res 26 19 (1998) 4524-4528
38. Soboll G., Horohov D.W., Aldridge B.M., Olsen C.W., McGregor M.W., Drape R.J., Macklin M.D., Swain W.F., and Lunn D.P. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet Immunol Immunopathol 94 (2003) 47-62
39. Sofer G., and Hagel L. Handbook of Process Chromatography: A Guide to Optimization Scale-Up and Validation (1994), Academic press, San Diego
40. Tanghe A., D'Souza S., Rosseels V., Denis O., Ottenhoff T.H.M., Dalemans W., Wheeler C., and Huygen K. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 69 (2001) 3041-3047
41. Ulmer J.B., Sadoff J.C., and Liu M.A. DNA vaccines. Curr Opin Immunol 8 4 (1996) 531-536
42. United Nations, D.o.E.a.S.A., Population Division, 2006 Revision of World Populations Prospects, 2006.
43. United States General Accounting Office, 'Influenza Pandemic: Plan Needed for Federal and State Response' 2000, Report to Congressional Requesters, GAO-01-4.
44. Varley D.L., Hitchcock A.G., Weiss A.M., Horler W.A., Cowell R., Peddie L., Sharpe G.S., Thatcher D.R., and Hanak J.A. Production of plasmid DNA for human gene therapy using modified alkaline cell lysis and expanded bed anion exchange chromatography. Bioseparation 8 1-5 (1999) 209-217
45. Wang Z., Le G., Shi W., and Wegrzyn G. Medium design for plasmid DNA production based on stoichiometric model. Proc Biochem 36 (2001) 1085-1093
46. Wils P., Escriou V., Warnery A., Lacroix F., Lagneaux D., Ollivier M., Crouzet J., Mayaux J.F., and Scherman D. Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography. Gene Therapy 4 (1997) 323-330
47. Yamakawa H., Higashino K.-i., and Ohara O. Sequence-dependent DNA separation by anion-exchange high-performance liquid chromatography. Anal Biochem 240 2 (1996) 242-250
48. Yee L., and Blanch H.W. Recombinant protein expression in high cell density fed-batch cultures of Escherichia coli. Biotechnology (NY) 10 12 (1992) 1550-1556
49. Zabriskie D., and Arcuri E. Factors influencing the productivity of fermentations employing recombinant microorganisms. Enz Microbiol Technol 8 (1986) 706-717